Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Nasopharyngeal Carcinoma 6Colorectal Neoplasms 4Lung Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Squamous Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Neuroblastoma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, T-Cell 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Cancer Organoids 1Advanced Pancreatic Cancer 1Adenoviridae Infections 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 25pembrolizumab 20Ipilimumab 15toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Cyclophosphamide 6Blood Specimen Collection 6trametinib 5fludarabine 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5durvalumab 4binimetinib 4aldesleukin 4Interleukin-2 4Injections 4Carboplatin 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Paclitaxel 3Introns 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Melanoma × Endostatins × Clear all
NCT03095079 2017-03-29

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡